July 1st, 2008 by allsoch
A biomedical engineering assistant professor at The University of Texas at Austin has been awarded a $1.5 million National Institutes of Health/National Cancer Institute grant to conduct nanoparticle cancer research.
Read the rest of this entry »
Posted in Uncategorized | No Comments »
July 1st, 2008 by allsoch
ORLANDO, FL (UroToday.com) - In this interesting study, Dr. Janet Colli and colleagues evaluated whether prostate cancer (CaP) death rates correlated with PSA screening and with the number of urologists per unit of population.
Read the rest of this entry »
Posted in Uncategorized | No Comments »
July 1st, 2008 by allsoch
ORLANDO, FL (UroToday.com) - In a certain proportion of prostate cancers, the prostate-specific androgen-regulated gene TMPRSS2 is fused with the gene for the transcription factor ERG.This gene fusion product may have prognostic significance in men with the CaP; however, the exact prevalence of the genetic abnormality is debated.
Read the rest of this entry »
Posted in Uncategorized | No Comments »
July 1st, 2008 by allsoch
ORLANDO, FL (UroToday.com) - Although reduction in prostate cancer mortality rates is important, it is necessary to consider the effects of prostate cancer screening and treatment on patient quality of life. Potential gains in survival could be more than offset decrements in quality of life that may result from diagnosis and treatment.
Read the rest of this entry »
Posted in Uncategorized | No Comments »
July 1st, 2008 by allsoch
ORLANDO, FL (UroToday.com) - Pathologic stage T0 (pT0) rates following radical cystectomy (RC) alone range from 10-15%. The pT0 rate increases in patients that have received neoadjuvant platinum-based chemotherapy.
Read the rest of this entry »
Posted in Uncategorized | No Comments »
July 1st, 2008 by allsoch
At the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology’s 2008 International Symposium on Supportive Care in Cancer (MASCC / ISOO) held last week in Houston, Texas, The GI Company reported secondary endpoints relating to Oral Mucositis Assessment Scale (OMAS) scores from the Company’s Phase II clinical study, designed to evaluate the safety and efficacy of its lead clinical compound, Intestinal Trefoil Factor (rhITF) Oral Spray, in development for oral mucositis.
Read the rest of this entry »
Posted in Uncategorized | No Comments »
July 1st, 2008 by allsoch
Percutaneous radiofrequency ablation - a minimally invasive treatment technique that heats and destroys cancer cells - achieves a high rate of sustained complete responses in selected patients with lung tumours, according to results from the first prospective study of patients treated with technique.
Read the rest of this entry »
Posted in Uncategorized | No Comments »
July 1st, 2008 by allsoch
Smoke-free policies reduce the exposure of both adults and children, reduce the prevalence of smoking in adults and reduce the risk of heart disease related to smoke exposure. A resulting reduction in the lung cancer burden may well occur as a result of these policies, but relevant evidence will only become available some time in the future.
Read the rest of this entry »
Posted in Uncategorized | No Comments »
July 1st, 2008 by allsoch
A new targeted drug therapy developed at The Institute of Cancer Research is showing positive results in killing tumour cells of some common cancers in the laboratory, according to a study published in Clinical Cancer Research today (July 1).
Read the rest of this entry »
Posted in Uncategorized | No Comments »